Reconstructing hemoglobin-based oxygen carriers

Transfusion

Volumn 50, Issue 12, 2010, Pages 2764-2767

  Greenburg, A G ^a,b,c   Light, W R ^a   Dube G P ^a,d  

^a Biopure Corporation   (United States)

^b BROWN UNIVERSITY   (United States)

^c TEI Biosciences ^*  (United States)

^d OPK Biotech   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; HEMOGLOBIN BASED OXYGEN CARRIER; HEMOGLOBIN GLUTAMER 200; NITRIC OXIDE; POLYMERIZED HEMOGLOBIN; UNCLASSIFIED DRUG;

DRUG BINDING; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HUMAN; INJURY; LETTER; NONHUMAN; RISK BENEFIT ANALYSIS; VASOCONSTRICTION;

ANEMIA; ANIMALS; BLOOD SUBSTITUTES; DRUG STORAGE; DRUG TOXICITY; HEALTH PLANNING GUIDELINES; HEMOGLOBINS; HUMANS; META-ANALYSIS AS TOPIC; OXYGEN; POSTOPERATIVE COMPLICATIONS; RISK ASSESSMENT; VASOCONSTRICTION;

EID: 78649985807     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2010.02814.x     Document Type: Letter

References (29)

1. Hess JR,. Deconstructing hemoglobin-based oxygen carriers. Transfusion 2008; 48: 2051-2.
2. Natanson C, Kern SJ, Lurie P, Banks SM, Wolfe SM,. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA 2008; 299: 2304-12. Epub 2008 Apr 28. Erratum in: JAMA 2008 Sep 17;300(11): 1300.
3. Levien LJ, Hodgson RE, James MF,. Hemoglobin-based blood substitutes and risk of myocardial infarction and death. [Letter]. JAMA 2008; 300: 1295.
4. Keipert PE, Olofsson C, Winslow RM,. Hemoglobin-based blood substitutes and risk of myocardial infarction and death. [Letter]. JAMA 2008; 300: 1295-6.
5. Shander A, Javidroozi M, Thompson G,. Hemoglobin-based blood substitutes and risk of myocardial infarction and death. [Letter]. JAMA 2008; 300: 1296-7.
6. Sauaia A, Moore EE, Banerjee A,. Hemoglobin-based blood substitutes and risk of myocardial infarction and death. [Letter]. JAMA 2008; 300: 1297.
7. Mackenzie CF, Moon-Massat PF, Shander A, Javidroozi A, Greenburg G,. When blood is not an option: factors affecting survival after use of a hemoglobin-based oxygen carrier in 54 patients with life-threatening anemia. Anesth Analg 2010; 110: 685-93.
8. Sapa. MCC approves cattle blood meds. Times Live, Johannesburg South Africa. 2010.
9. Shea BJ, Hamel C, Wells GA, Bouter LM, Kristjansson E, Grimshaw J, Henry DA, Boers M,. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol 2009; 62: 1013-20.
10. Biopure Biological License Application (BLA) submitted to FDA. 2002.
11. Hochstein HD, Fitzgerald EA, Vargas R,. Properties of US standard endotoxin (EC-5) in human male volunteers. J Endotoxin Res 1994; 1: 52-6.
12. Cabrales P, Tsai A, Intaglietta M,. Balance between vasoconstriction and enhanced oxygen delivery. Transfusion 2008; 48: 2087-95.
13. 2 measurements in the microcirculation using phosphorescence quenching microscopy at high magnification. Am J Physiol Heart Circ Physiol 2008; 294: H2905-H2916.
14. Mongan PD, Moon-Massat PF, Rentko V, Mihok S, Dragovich A, Sharma P,. Regional blood flow after serial normovolemic exchange transfusion with HBOC-201 (Hemopure) in anesthetized swine. J Trauma 2009; 67: 51-60.
15. Serruys PW, Vranckx P, Slagboom T, Regar E, Meliga E, De Winter RJ, Heyndrickx G, Schuler G, Van Remortel EA, Dubé GP, Symons J, for the COR-0001 trial investigators. Hemodynamic effects, safety, and tolerability of hemoglobin-based oxygen carrier-201 (HBOC-201) in patients undergoing PCI for CAD. EuroInterv 2008; 3: 600-9.
16. Te Lintel HM, Dubé GP, Regar E, De Boer M, Vranckx P, Van Der Giessen WJ, Serruys PW, Duncker DJ,. Preoxygenated hemoglobin-based oxygen carrier HBOC-201 annihilates myocardial ischemia during brief coronary artery occlusion in pigs. Am J Physiol Heart Circ Physiol 2010; 298: H1103-13.
17. Meliga E, Vranckx P, Regar E, Kint PP, Duncker DJ, Serruys PW,. Proof-of-concept trial to evaluate haemoglobin based oxygen therapeutics in elective percutaneous coronary revascularisation. Rationale, protocol design and haemodynamic results. EuroInterv 2008; 4: 99-107.
18. Winslow RM,. MP4, a new nonvasoactive polyethylene glycol-hemoglobin conjugate. Artif Organs 2004; 28: 800-6.
19. Dubé GP, Vranckx P, Greenburg AG,. HBOC-201: the multi-purpose oxygen therapeutic. EuroInterv 2008; 4: 161-5.
20. Bucci E, Kwansa H, Koehler RC, Matheson B,. Development of zero-link polymers of hemoglobin, which do not extravasate and do not induce pressure increases upon infusion. Artif Cells Blood Substit Immobil Biotechnol 2007; 35: 11-8.
21. Matheson B, Kwansa HE, Bucci E, Rebel A, Koehler RC,. Vascular response to infusions of a nonextravasating hemoglobin polymer. J Appl Physiol 2002; 93: 1479-86.
22. Johnson JL, Moore EE, Offner PJ, Haenel JB, Hides GA, Tamura DY,. Resuscitation of the injured patient with polymerized stroma-free hemoglobin does not produce systemic or pulmonary hypertension. Am J Surg 1998; 176: 612-7.
23. Björkholm M, Fagrell B, Przybelski R, Winslow N, Young M, Winslow RM,. A phase I single blind clinical trial of a new oxygen transport agent (MP4), human hemoglobin modified with maleimide-activated polyethylene glycol. Haematologica 2005; 90: 505-15. PubMed PMID: 15820947.
24. Young MA, Riddez L, Kjellström BT, Winslow RM,. Effect of maleimide-polyethylene glycol hemoglobin (MP4) on hemodynamics and acid-base status after uncontrolled hemorrhage in anesthetized swine: comparison with crystalloid and blood. J Trauma 2007; 63: 1234-44. PubMed PMID: 18212644.
25. Jahr JS, Mackenzie C, Pearce LB, Pitman A, Greenburg AG,. HBOC-201 as an alternative to blood transfusion: efficacy and safety evaluation in a multicenter Phase III trial in elective orthopedic surgery. J Trauma 2008; 64: 1484-97.
26. Rice J, Philbin N, Light R, Arnaud F, Steinbach T, McGwin G, Collier S, Malkevich N, Moon-Massatt P, Rentko V, Pearce LB, Ahlers S, McCarron R, Handrigan M, Freilich D,. The effects of decreasing low-molecular weight hemoglobin components of hemoglobin-based oxygen carriers in swine with hemorrhagic shock. J Trauma 2008; 64: 1240-57.
27. Manning JE, Katz LM, Brownstein MR, Pearce LB, Gawryl MS, Baker CC,. Bovine hemoglobin-based oxygen carrier (HBOC-201) for resuscitation of uncontrolled, exsanguinating liver injury in swine. Carolina Resuscitation Research Group. Shock 2000; 13: 152-9.
28. Katz LM, Manning JE, McCurdy S, Pearce LB, Gawryl MS, Wand Y, Brown C, Carolina Resuscitation Research Group. HBOC-201 improves survival in a swine model of hemorrhagic shock and liver injury. Resuscitation 2002; 54: 77-87.
29. Arnaud F, Hammett M, Asher L, Philbin N, Rice J, Dong F, Pearce B, Flournoy WS, Nicholson C, Mccarron R, Freilich D,. Effects of bovine polymerized hemoglobin on coagulation in controlled hemorrhagic shock in swine. Shock 2005; 24: 145-52.